KemPharm Inc., a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, has confirmed receipt of a regulatory milestone payment of $10 million for the FDA approval of Azstarys in accordance with the recently amended definitive collaboration and license agreement with Commave Therapeutics, SA, an affiliate of Gurnet Point Capital.   The License Agreement provides for an exclusive worldwide license to develop, manufacture and commercialize KemPharm’s p...